ONYX ANEURYSM

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a 01,03 report with the FDA on 2015-04-03 for ONYX ANEURYSM manufactured by Irvine.

Event Text Entries

[5600706] Citation: ronie peske et al. Evaluation of onyx hd-500 embolic system in the treatment of 84 wide neck intracranial aneurysms. Neurosurgery vol. 64 number 5. May 2009. Medtronic (covidien) received information through literature review and the following event(s) were captured as a result of the review: sixty- nine patients with 84 aneurysms were treated. Most of the aneurysms were located in the anterior circulation (80 of 84 aneurysms), were unruptured (74 of 84 aneurysms), and were incidental. Ten presented with subarachnoid hemorrhage, and 15 were symptomatic. All aneurysms had wide necks (neck _4 mm and/or dome- to- neck ratio_1. 5). Fifty aneurysms were small (_12 mm), 30 were large (12 to _25 mm) and 4 were giant. Angiographic follow- up was available for 65 of the 84 aneurysms at 6 months, for 31 of the 84 aneurysms at 18 months, and for 5 of the 84 aneurysms at 36 months. Onyx leakage (onyx extravasation) occurred in 18 patients. It was mild in 10, moderate in six and severe in two. Internal carotid artery stenosis and thrombosis was seen in one patient (5 months after treatment). Severe internal carotid artery stenosis (50% of the lumen) occurred in four patients. Onyx extravasation was in two of these patients, and moderate extravasation occurred in one patient, there was no extravasation in one patient. At the clinical follow-up at 6 months, the mass effect was cured in four patients. There was partial improvement in two patients (optic nerve) and no change in three patients. (two with six nerve lesions and one with third nerve palsy). In two of these patients, the symptoms initially worsened (third and sixth cranial nerves), with regression to the previous state in 15 days in one patient and in 3 months in the other. Two patients developed a new cranial nerve deficit after treatment; 1 patient presented with new compression of the optic nerve with permanent visual deficiency, and the presented with temporary sixth nerve palsy. Of the aneurysms with optic nerve compression, only minor improvement was seen after embolization in both cases. Information received from the same article as mfr #s 2029214-2015-00317, 2029214-2015-00337.
Patient Sequence No: 1, Text Type: D, B5


[13037090] Http://www. Ncbi. Nlm. Nih. Gov/pubmed/19404128. The lot history record review was not possible since the lot number was not reported. The onyx were not returned for analysis; therefore the event causes could not be determined. The events occurred in the patients during procedure and post procedure and their causes were unknown. (b)(4).
Patient Sequence No: 1, Text Type: N, H10


MAUDE Entry Details

Report Number2029214-2015-00326
MDR Report Key4659390
Report Source01,03
Date Received2015-04-03
Date of Report2015-03-05
Date of Event2008-07-08
Date Mfgr Received2015-03-05
Date Added to Maude2015-04-03
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA0
Event Location0
Manufacturer ContactMRS. TRICHA MILES
Manufacturer Street9775 TOLEDO WAY
Manufacturer CityIRVINE 92618
Manufacturer CountryUS
Manufacturer Postal92618
Manufacturer Phone9496801224
Manufacturer G1IRVINE
Manufacturer Street9775 TOLEDO WAY
Manufacturer CityIRVINE CA 92618
Manufacturer CountryUS
Manufacturer Postal Code92618
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameONYX ANEURYSM
Generic NamePOLYMERIZING, NEUROVASCULAR EMBOLIZATION MATERIAL
Product CodeOBA
Date Received2015-04-03
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device Eval'ed by MfgrR
Device Sequence No1
Device Event Key0
ManufacturerIRVINE
Manufacturer Address9775 TOLEDO WAY IRVINE CA 92618 US 92618


Patients

Patient NumberTreatmentOutcomeDate
101. Other; 2. Deathisabilit 2015-04-03

© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.